Utility of social media and crowd-sourced data for pharmacovigilance: a scoping review protocol

Introduction Adverse events associated with medications are under-reported in postmarketing surveillance systems. A systematic review of published data from 37 studies worldwide (including Canada) found the median under-reporting rate of adverse events to be 94% in spontaneous reporting systems. This scoping review aims to assess the utility of social media and crowd-sourced data to detect and monitor adverse events related to health products including pharmaceuticals, medical devices, biologics and natural health products. Methods and analysis Our review conduct will follow the Joanna Briggs Institute scoping review methods manual. Literature searches were conducted in MEDLINE, EMBASE and the Cochrane Library from inception to 13 May 2016. Additional sources included searches of study registries, conference abstracts, dissertations, as well as websites of international regulatory authorities (eg, Food and Drug Administration (FDA), the WHO, European Medicines Agency). Search results will be supplemented by scanning the references of relevant reviews. We will include all publication types including published articles, editorials, websites and book sections that describe use of social media and crowd-sourced data for surveillance of adverse events associated with health products. Two reviewers will perform study selection and data abstraction independently, and discrepancies will be resolved through discussion. Data analysis will involve quantitative (eg, frequencies) and qualitative (eg, content analysis) methods. Dissemination The summary of results will be sent to Health Canada, who commissioned the review, and other relevant policymakers involved with the Drug Safety and Effectiveness Network. We will compile and circulate a 1-page policy brief and host a 1-day stakeholder meeting to discuss the implications, key messages and finalise the knowledge translation strategy. Findings from this review will ultimately inform the design and development of a data analytics platform for social media and crowd-sourced data for pharmacovigilance in Canada and internationally. Registration details Our protocol was registered prospectively with the Open Science Framework (https://osf.io/kv9hu/).

[1]  Kevin A Padrez,et al.  Twitter as a Tool for Health Research: A Systematic Review , 2017, American journal of public health.

[2]  J. McGowan,et al.  PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. , 2016, Journal of clinical epidemiology.

[3]  Mark Dredze,et al.  Combining Search, Social Media, and Traditional Data Sources to Improve Influenza Surveillance , 2015, PLoS Comput. Biol..

[4]  Henrik Druid,et al.  Incidence of fatal adverse drug reactions: a population based study. , 2008, British journal of clinical pharmacology.

[5]  Michael J. Paul,et al.  National and Local Influenza Surveillance through Twitter: An Analysis of the 2012-2013 Influenza Epidemic , 2013, PloS one.

[6]  Zion Tsz Ho Tse,et al.  Social Media's Initial Reaction to Information and Misinformation on Ebola, August 2014: Facts and Rumors , 2016, Public health reports.

[7]  M. Ibara,et al.  Regulatory Definitions and Good Pharmacovigilance Practices in Social Media , 2015, Therapeutic innovation & regulatory science.

[8]  A. Tricco,et al.  Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis , 2013, Canadian Medical Association Journal.

[9]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation , 2016, British Medical Journal.

[10]  G. Eysenbach,et al.  Pandemics in the Age of Twitter: Content Analysis of Tweets during the 2009 H1N1 Outbreak , 2010, PloS one.

[11]  Mark McClellan,et al.  Drug safety reform at the FDA--pendulum swing or systematic improvement? , 2007, The New England journal of medicine.

[12]  Michael J. Paul,et al.  Twitter Improves Influenza Forecasting , 2014, PLoS currents.

[13]  S. Golder,et al.  Systematic review on the prevalence, frequency and comparative value of adverse events data in social media. , 2015, British journal of clinical pharmacology.

[14]  Mark Dredze,et al.  Malpractice and Malcontent: Analyzing Medical Complaints in Twitter , 2012, AAAI Fall Symposium: Information Retrieval and Knowledge Discovery in Biomedical Text.

[15]  H. Arksey,et al.  Scoping studies: towards a methodological framework , 2005 .

[16]  Patricia McInerney,et al.  The Joanna Briggs Institute reviewers' manual 2015: methodology for JBI scoping reviews , 2015 .

[17]  Sharon E. Straus,et al.  A scoping review on the conduct and reporting of scoping reviews , 2016, BMC Medical Research Methodology.

[18]  Michael D. Barnes,et al.  Tracking suicide risk factors through Twitter in the US. , 2014, Crisis.

[19]  E. Larson,et al.  Dissemination of health information through social networks: twitter and antibiotics. , 2010, American journal of infection control.

[20]  Yi Hao,et al.  Chinese Social Media Reaction to Information about 42 Notifiable Infectious Diseases , 2015, PloS one.

[21]  Robert L Cook,et al.  Evaluating Google, Twitter, and Wikipedia as Tools for Influenza Surveillance Using Bayesian Change Point Analysis: A Comparative Analysis , 2016, JMIR public health and surveillance.

[22]  A. Burgun,et al.  Adverse Drug Reaction Identification and Extraction in Social Media: A Scoping Review , 2015, Journal of medical Internet research.

[23]  G. Eysenbach Infodemiology and Infoveillance: Framework for an Emerging Set of Public Health Informatics Methods to Analyze Search, Communication and Publication Behavior on the Internet , 2009, Journal of medical Internet research.

[24]  P. Stone Popping the (PICO) question in research and evidence-based practice. , 2002, Applied nursing research : ANR.

[25]  Zion Tsz Ho Tse,et al.  Social Media's Initial Reaction to Information and Misinformation on Ebola , 2016 .

[26]  Manuel Gomez,et al.  Evaluation of the Extent of Under-Reporting of Serious Adverse Drug Reactions , 2004, Drug safety.